Skip to main content
Canadian Journal of Public Health = Revue Canadienne de Santé Publique logoLink to Canadian Journal of Public Health = Revue Canadienne de Santé Publique
editorial
. 2009 Nov 1;100(6):475–477. doi: 10.1007/BF03404348

Biliary Atresia: The Timing Needs a Changin’

Ehsan Chitsaz 119,219, Richard A Schreiber 119,219,319,, Jean-Paul Collet 219,319, Janusz Kaczorowski 319,419,519
PMCID: PMC6973595  PMID: 20209745

Abstract

Biliary atresia (BA), a uniquely pediatric liver disease, is the leading cause of liver-related death in children and the most frequent indication for liver transplantation in the pediatric population. Early intervention with a Kasai procedure (KP) is the current standard of care for this condition. The single most important and well-established prognostic factor for the KP outcome is the patient‘s age at the time of the KP. The older the infant, the less successful the operation and the less favourable is the post-KP survival with native liver. There remains in Canada, and throughout the world, a problem of late referral, delayed diagnosis and older age at surgery. Early disease detection and intervention has been hampered by the lack of an effective screening strategy for BA. Recently, however, novel programs for the early identification of BA in the first month of life, but after two weeks of age, have been successfully implemented and evaluated in some countries, with significantly improved outcomes for affected infants. Whether any of these programs should be adopted to improve the timing of referral and treatment for Canadian infants affected with this devastating liver disease deserves consideration and study.

Key words: Pediatric liver disease, neonatal cholestasis, newborn screening

References

  • 1.Hanley WB. Newborn screening in Canada–Are we out of step? Paediatr Child Health. 2005;10(4):203–7. doi: 10.1093/pch/10.4.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wilson JMG, Junger G. Principles and Practice of Screening for Disease. Geneva: WHO; 1968. [Google Scholar]
  • 3.Schreiber RA, Kleinman RE. Biliary atresia. J Pediatr Gastroenterol Nutr. 2002;35(Suppl1):S11–S16. doi: 10.1097/00005176-200207001-00005. [DOI] [PubMed] [Google Scholar]
  • 4.Balistreri WF, Grand R, Hoofnagle JH, Suchy FJ, Ryckman FC, Perlmutter DH, et al. Biliary atresia: Current concepts and research directions. Summary of a symposium. Hepatology. 1996;23:1682–92. doi: 10.1002/hep.510230652. [DOI] [PubMed] [Google Scholar]
  • 5.Schreiber RA, Barker CC, Roberts EA, Martin SR, Alvarez F, Smith L, Canadian Pediatric Hepatology Research Group et al. Biliary atresia: The Canadian experience. J Pediatr. 2007;151(6):659–65. doi: 10.1016/j.jpeds.2007.05.051. [DOI] [PubMed] [Google Scholar]
  • 6.Petersen C, Harder D, Abola Z, Alberti D, Becker T, Chardot C, et al. European biliary atresia registries: Summary of a symposium. Eur J Pediatr Surg. 2008;18(2):111–16. doi: 10.1055/s-2008-1038479. [DOI] [PubMed] [Google Scholar]
  • 7.Sokol RJ, Shepherd RW, Superina R, Bezerra JA, Robuck P, Hoofnagle JH. Screening and outcomes in biliary atresia: Summary of a National Institutes of Health workshop. Hepatology. 2007;46(2):566–81. doi: 10.1002/hep.21790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Meyers RL, Book LS, O’Gorman MA, Jackson WD, Black RE, Johnson DG, et al. High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia. J Pediatr Surg. 2003;38(3):406–11. doi: 10.1053/jpsu.2003.50069. [DOI] [PubMed] [Google Scholar]
  • 9.A randomized, double-blinded, placebo-controlled trial of corticosteroid therapy following portoenterostomy. Available at: https://doi.org/clinicaltrials.gov/ct2/show/NCT00294684?term=biliary+atresia+and+US&rank=2 (Accessed May 1, 2009).
  • 10.Davenport M, De Ville de Goyet J, Stringer MD, Mieli-Vergani G, Kelly DA, McClean P, et al. Seamless management of biliary atresia in England and Wales (1999–2002) Lancet. 2004;363:1354–57. doi: 10.1016/S0140-6736(04)16045-5. [DOI] [PubMed] [Google Scholar]
  • 11.Serinet MO, Broué P, Jacquemin E, Lachaux A, Sarles J, Gottrand F, et al. Management of patients with biliary atresia in France: Results of a decentralized policy 1986–2002. Hepatology. 2006;44(1):75–84. doi: 10.1002/hep.21219. [DOI] [PubMed] [Google Scholar]
  • 12.Serinet MO, Wildhaber BE, Broué P, Lachaux A, Sarles J, Jacquemin E, et al. Impact of age at Kasai operation for biliary atresia screening. Pediatrics. 2009;123:1280–86. doi: 10.1542/peds.2008-1949. [DOI] [PubMed] [Google Scholar]
  • 13.Canadian Pediatric Society. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation) — summary. Paediatr Child Health. 2007;12(5):401–18. doi: 10.1093/pch/12.5.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lai MW, Chang MH, Hsu SC, Hsu HC, Su CT, Kao CL, et al. Differential diagnosis of extrahepatic biliary atresia from neonatal hepatitis: A prospective study. J Pediatr Gastroenterol Nutr. 1994;18:121–27. doi: 10.1097/00005176-199402000-00001. [DOI] [PubMed] [Google Scholar]
  • 15.Keffler S, Kelly DA, Powell JE, Green A. Population screening for neonatal liver disease: A feasibility study. J Pediatr Gastroenterol Nutr. 1998;27:306–11. doi: 10.1097/00005176-199809000-00007. [DOI] [PubMed] [Google Scholar]
  • 16.Hsiao CH, Chang MH, Chen HL, Lee HC, Wu TC, Lin CC, et al. Taiwan Infant Stool Colour Card Study Group. Universal screening for biliary atresia using an infant stool colour card in Taiwan. Hepatology. 2008;47(4):1233–40. doi: 10.1002/hep.22182. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Journal of Public Health = Revue Canadienne de Santé Publique are provided here courtesy of Springer

RESOURCES